
Scotland approves targetted combination therapy for advanced melanoma
pharmafile | February 11, 2020 | News story | Manufacturing and Production | NHS, SMC, Scotland, UK, advanced melanoma, melanoma
The Scottish Medicines Consortium (SMC) has approved targeted combination therapy for the treatment of adult patient with unresectable or metastatic melanoma with a BRAF V600 mutation.
The approval means that encorafenib plus binimetinibi will be used as the first and only targeted therapy available in Scotland for both treatment-naïve and previously treated settings.
This will help improve survival rates. It will more than double median progression-free survival from 7.3 months with BRAF inhibitor monotherapy to 14.9 months. It will also deliver median overall survival from 16.9 months with BRAF inhibitor monotherapy to 33.6 months.
The targeted therapy is already available in the rest of the UK. MASScot, a Scottish melanoma patient group, said the approval is something they have been “pleading for” for a long time. The number of deaths from the disease in Scotland has risen by 20% in the last twenty years.
Melanoma is one of the deadliest forms of skin cancer, and around half of the melanoma patients have a BRAF mutation which has a poorer prognosis and a higher risk of death when the cancer has spread.
Conor Kavanagh
Related Content

Five Facts about NHS and primary care
1 Primary care is the front door to the NHS, but it extends well beyond …

Major funding opportunity opens for early cancer diagnostics
Up to £25.4m in funding is available for collaborative projects developing technologies to improve the …

Scots neonatal innovations target hearing loss and earlier care
Scottish healthcare teams are introducing a range of innovations aimed at improving outcomes for newborns, …





